Literature DB >> 27798881

Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.

Maximilian Christian Kriegmair1, Matthias Balk2, Ralph Wirtz3, Annette Steidler2, Cleo-Aron Weis4, Johannes Breyer5, Arndt Hartmann6, Christian Bolenz7, Philipp Erben2.   

Abstract

AIM: To evaluate the prognostic role of the p53-upstream inhibitors MDM2, MDM4 and its splice variant MDM4-S in patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).
MATERIALS AND METHODS: mRNA Expression levels of MDM2, MDM4 and MDM4-S were assessed by quantitative real-time polymerase chain reaction (qRT-PCR) in 75 RC samples. Logistic regression analyses identified predictors of recurrence-free (RFS) and cancer-specific survival (CSS).
RESULTS: High expression was found in 42% (MDM2), 27% (MDMD4) and 91% (MDM4-S) of tumor specimens. Increased MDM2 expression was significantly associated with higher tumor stage (p=0.05) and lymphovascular invasion (LVI) (p=0.041). In the univariate analysis, low MDM4 expression (hazard ratio (HR)=5.93; p=0.002; HR=3.00; p=0.047), but not MDM2 (HR=1.63; p=0.222; HR=1.59; p=0.27), were associated with RFS and CSS. In the multivariate analysis, the combination of low MDM4 and high MDM2 was significant for RFS and CSS (HR=14.9; p=0.001; HR=5.63; p=0.019).
CONCLUSION: The combination of MDM2 and MDM4 expression is an independent predictor in patients undergoing RC for MIBC. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  HDMX; MDM2; bladder cancer; marker; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27798881     DOI: 10.21873/anticanres.11091

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer.

Authors:  Daniel Uysal; Karl-Friedrich Kowalewski; Maximilian Christian Kriegmair; Ralph Wirtz; Zoran V Popovic; Philipp Erben
Journal:  PLoS One       Date:  2021-03-12       Impact factor: 3.240

2.  LncRNA SNHG1 Facilitates Tumor Proliferation and Represses Apoptosis by Regulating PPARγ Ubiquitination in Bladder Cancer.

Authors:  Hongzhou Cai; Haifei Xu; Hongcheng Lu; Weizhang Xu; Haofeng Liu; Xinwei Wang; Guoren Zhou; Xuejian Yang
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

3.  Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.

Authors:  Gang Wang; Peter C Black; Peter J Goebell; Lingyun Ji; Carlos Cordon-Cardo; Bernd Schmitz-Dräger; Debra Hawes; Bogdan Czerniak; Sarah Minner; Guido Sauter; Frederic Waldman; Susan Groshen; Richard J Cote; Colin P Dinney
Journal:  Urol Oncol       Date:  2021-02-07       Impact factor: 2.954

4.  Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Authors:  M C Kriegmair; R M Wirtz; T S Worst; J Breyer; M Ritter; B Keck; C Boehmer; W Otto; M Eckstein; C A Weis; A Hartmann; C Bolenz; P Erben
Journal:  Transl Oncol       Date:  2018-02-23       Impact factor: 4.243

5.  CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Authors:  Thomas S Worst; Cleo-Aron Weis; Robert Stöhr; Simone Bertz; Markus Eckstein; Wolfgang Otto; Johannes Breyer; Arndt Hartmann; Christian Bolenz; Ralph M Wirtz; Philipp Erben
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379

6.  mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Authors:  Markus Eckstein; Ralph Markus Wirtz; Matthias Gross-Weege; Johannes Breyer; Wolfgang Otto; Robert Stoehr; Danijel Sikic; Bastian Keck; Sebastian Eidt; Maximilian Burger; Christian Bolenz; Katja Nitschke; Stefan Porubsky; Arndt Hartmann; Philipp Erben
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923

7.  Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.

Authors:  Shiyu Mao; Junfeng Zhang; Yadong Guo; Ziwei Zhang; Yuan Wu; Wentao Zhang; Longsheng Wang; Jiang Geng; Yang Yan; Xudong Yao
Journal:  Drug Des Devel Ther       Date:  2019-01-11       Impact factor: 4.162

8.  Simultaneous inhibition of atypical protein kinase‑C and mTOR impedes bladder cancer cell progression.

Authors:  Rekha Patel; Sm Anisul Islam; Raja Reddy Bommareddy; Tracess Smalley; Mildred Acevedo-Duncan
Journal:  Int J Oncol       Date:  2020-03-20       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.